Ken Takezawa

2.1k total citations · 1 hit paper
19 papers, 1.7k citations indexed

About

Ken Takezawa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ken Takezawa has authored 19 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Ken Takezawa's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (8 papers) and Cancer therapeutics and mechanisms (4 papers). Ken Takezawa is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (8 papers) and Cancer therapeutics and mechanisms (4 papers). Ken Takezawa collaborates with scholars based in Japan and United States. Ken Takezawa's co-authors include Kazuhiko Nakagawa, Isamu Okamoto, Kazuto Nishio, Kiyoko Kuwata, Haruka Yamaguchi, Junko Tanizaki, Yelena Y. Janjigian, Vincent A. Miller, Erina Hatashita and Valentina Pirazzoli and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Ken Takezawa

19 papers receiving 1.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

2012 555 citations Ken Takezawa, Valentina Pirazzoli et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ken Takezawa Japan	14	1.0k	978	969	271	187	19	1.7k
Silvia La Monica Italy	32	1.0k 1.0×	1.2k 1.2×	1.1k 1.1×	367 1.4×	155 0.8×	67	2.2k
Weiwei Tan United States	20	1.2k 1.2×	1.0k 1.1×	809 0.8×	232 0.9×	188 1.0×	59	1.9k
Shundong Cang China	21	679 0.7×	779 0.8×	1.4k 1.4×	485 1.8×	229 1.2×	80	2.3k
Lisa Drew United States	18	882 0.9×	1.2k 1.2×	1.4k 1.4×	311 1.1×	289 1.5×	55	2.2k
Jin Kyung Rho South Korea	27	876 0.8×	1.2k 1.2×	1.4k 1.5×	718 2.6×	172 0.9×	80	2.6k
Natalie Ozburn United States	9	711 0.7×	770 0.8×	1.1k 1.1×	470 1.7×	113 0.6×	9	1.8k
Zhenfan Yang China	19	1.2k 1.2×	1.1k 1.1×	549 0.6×	308 1.1×	108 0.6×	39	1.8k
Patrick J. Grohar United States	19	623 0.6×	444 0.5×	1.1k 1.1×	234 0.9×	246 1.3×	45	1.7k
Uzma Asghar United Kingdom	11	1.3k 1.3×	1.6k 1.6×	923 1.0×	491 1.8×	249 1.3×	25	2.4k
Donald Thornton United States	19	372 0.4×	672 0.7×	890 0.9×	282 1.0×	293 1.6×	37	1.9k

Countries citing papers authored by Ken Takezawa

Since Specialization

Citations

This map shows the geographic impact of Ken Takezawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Takezawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Takezawa more than expected).

Fields of papers citing papers by Ken Takezawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Takezawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Takezawa. The network helps show where Ken Takezawa may publish in the future.

Co-authorship network of co-authors of Ken Takezawa

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Takezawa. A scholar is included among the top collaborators of Ken Takezawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Takezawa. Ken Takezawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Tanizaki, Junko, Isamu Okamoto, Takafumi Okabe, et al.. (2012). Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer. Clinical Cancer Research. 18(22). 6219–6226. 126 indexed citations

Takezawa, Ken, Valentina Pirazzoli, Maria E. Arcila, et al.. (2012). HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation. Cancer Discovery. 2(10). 922–933. 555 indexed citations breakdown →

Sakai, Kazuko, Isamu Okamoto, Ken Takezawa, et al.. (2012). A Novel Mass Spectrometry–Based Assay for Diagnosis of EML4-ALK–Positive Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 7(5). 913–918. 13 indexed citations

Tanizaki, Junko, Isamu Okamoto, Ken Takezawa, et al.. (2012). Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells. British Journal of Cancer. 106(4). 763–767. 47 indexed citations

Hasegawa, Yoshikazu, Isamu Okamoto, Ken Takezawa, et al.. (2012). A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer. Investigational New Drugs. 31(3). 599–604. 2 indexed citations

Sakai, Kazuko, Isamu Okamoto, Ken Takezawa, et al.. (2012). A Novel Mass Spectrometry-Based Assay for Diagnosis of EML4-ALK-Positive Non-Small-Cell Lung Cancer. Annals of Oncology. 23. xi103–xi103. 1 indexed citations

Takezawa, Ken, Isamu Okamoto, Kazuto Nishio, Pasi A. Jänne, & Kazuhiko Nakagawa. (2011). Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer. Clinical Cancer Research. 17(8). 2140–2148. 115 indexed citations

Takezawa, Ken, Isamu Okamoto, Wataru Okamoto, et al.. (2011). Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. British Journal of Cancer. 104(10). 1594–1601. 145 indexed citations

Tanizaki, Junko, Isamu Okamoto, Kunio Okamoto, et al.. (2011). MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations. Journal of Thoracic Oncology. 6(10). 1624–1631. 103 indexed citations

10.

Okamoto, Wataru, Isamu Okamoto, Takeshi Yoshida, et al.. (2010). Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition. Molecular Cancer Therapeutics. 9(5). 1188–1197. 58 indexed citations

11.

Okamoto, Kunio, Isamu Okamoto, Wataru Okamoto, et al.. (2010). Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for EGFR Mutations. Cancer Research. 70(24). 10402–10410. 75 indexed citations

12.

Takezawa, Ken, Isamu Okamoto, Junko Tanizaki, et al.. (2010). Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor. Molecular Cancer Therapeutics. 9(6). 1647–1656. 63 indexed citations

13.

Iwasa, Tsutomu, Isamu Okamoto, Ken Takezawa, et al.. (2010). Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. British Journal of Cancer. 103(1). 36–42. 55 indexed citations

14.

Tanizaki, Junko, Isamu Okamoto, Ken Takezawa, et al.. (2010). Synergistic Antitumor Effect of S-1 and HER2-Targeting Agents in Gastric Cancer withHER2Amplification. Molecular Cancer Therapeutics. 9(5). 1198–1207. 30 indexed citations

15.

Okamoto, Kazuki, et al.. (2009). Cisplatin and Etoposide Chemotherapy Combined with Early Concurrent Twice-daily Thoracic Radiotherapy for Limited-disease Small Cell Lung Cancer in Elderly Patients. Japanese Journal of Clinical Oncology. 40(1). 54–59. 5 indexed citations

16.

Takezawa, Ken, Isamu Okamoto, Kimio Yonesaka, et al.. (2009). Sorafenib Inhibits Non–Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells. Cancer Research. 69(16). 6515–6521. 83 indexed citations

17.

Takezawa, Ken, Isamu Okamoto, Junya Fukuoka, et al.. (2008). Large Cell Neuroendocrine Carcinoma of the Mediastinum with α-Fetoprotein Production. Journal of Thoracic Oncology. 3(2). 187–189. 12 indexed citations

18.

Takezawa, Ken, Isamu Okamoto, Masahiro Fukuoka, & Kazuhiko Nakagawa. (2008). Pharmacokinetic Analysis of Carboplatin and Etoposide in a Small Cell Lung Cancer Patient Undergoing Hemodialysis. Journal of Thoracic Oncology. 3(9). 1073–1075. 15 indexed citations

19.

Yamori, Takao, Shigeo Sato, Kazuto Yamazaki, et al.. (1999). Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel.. PubMed. 59(16). 4042–9. 246 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact